Investing.com - Design Therapeutics (NASDAQ: DSGN) reported second quarter EPS of $-0.36, $0.04 better than the analyst estimate of $-0.40. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.00.
Design Therapeutics's stock price closed at $7.33. It is up 5.01% in the last 3 months and down -71.33% in the last 12 months.
Design Therapeutics saw 1 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Design Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Design Therapeutics's Financial Health score is "fair performance".
Check out Design Therapeutics's recent earnings performance, and Design Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar